Glaukos (GKOS) Stock Forecast & Price Target

Compare

410 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GKOS Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Glaukos

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GKOS Stock 12 Month Forecast

Average Price Target

$139.10

▲(16.52% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $139.10 with a high forecast of $165.00 and a low forecast of $122.00. The average price target represents a 16.52% change from the last price of $119.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"82":"$82","103":"$103","124":"$124","145":"$145","166":"$166"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$165.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":139.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$139.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$122.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[82,103,124,145,166],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.47,121.12615384615384,124.7823076923077,128.43846153846152,132.0946153846154,135.75076923076924,139.40692307692308,143.06307692307692,146.71923076923076,150.37538461538463,154.03153846153845,157.68769230769232,161.34384615384616,{"y":165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.47,119.13384615384615,120.7976923076923,122.46153846153845,124.12538461538462,125.78923076923077,127.45307692307692,129.1169230769231,130.78076923076924,132.4446153846154,134.10846153846154,135.7723076923077,137.43615384615384,{"y":139.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.47,117.81846153846153,118.16692307692307,118.51538461538462,118.86384615384615,119.21230769230769,119.56076923076922,119.90923076923077,120.25769230769231,120.60615384615384,120.95461538461538,121.30307692307693,121.65153846153846,{"y":122,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":156.44,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.54,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.91,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.47,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$165.00

Average Price Target$139.10

Lowest Price Target$122.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brandon Vazquez

William Blair

Buy

―

Initiated

01/30/26

Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (NASDAQ: SENS), Perspective Therapeutics (NYSE MKT: CATX) and Glaukos (NYSE: GKOS)

Richard Newitter

Truist Financial

Buy

―

Reiterated

01/29/26

Analysts Are Bullish on These Healthcare Stocks: Capricor Therapeutics (CAPR), Tvardi Therapeutics (TVRD)

Danielle Antalffy

UBS

$145→$150

Buy

25.65%

Upside

Reiterated

01/29/26

UBS Keeps Their Buy Rating on Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

$122

Buy

2.19%

Upside

Reiterated

01/28/26

Wells sees potential upside after Glaukos' iDose repeat dosing label approvedWells sees potential upside after Glaukos' iDose repeat dosing label approved

Ryan Zimmerman

BTIG

$123→$131

Buy

9.73%

Upside

Reiterated

01/28/26

Glaukos (GKOS) Receives a Buy from BTIG

Thomas Stephan

Stifel Nicolaus

$160

Buy

34.03%

Upside

Reiterated

01/26/26

Stifel Nicolaus Remains a Buy on Glaukos (GKOS)

Adam Maeder

Piper Sandler

$165

Buy

38.21%

Upside

Reiterated

01/20/26

Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Glaukos (GKOS)

David Saxon

Needham

$125

Buy

4.71%

Upside

Reiterated

01/14/26

Glaukos: Solid Fundamentals, Strong Multi-Segment Growth, and iDose Trajectory Support a Buy Rating Despite Near-Term Volatility

David Roman

Goldman Sachs

$112→$138

Buy

15.60%

Upside

Reiterated

01/09/26

Glaukos price target raised to $138 from $112 at Goldman SachsGlaukos price target raised to $138 from $112 at Goldman Sachs

Mason Carrico

Stephens

$115→$145

Buy

21.46%

Upside

Reiterated

01/02/26

Glaukos price target raised to $145 from $115 at StephensGlaukos price target raised to $145 from $115 at Stephens

Joanne Wuensch

Citi

$113→$125

Buy

4.71%

Upside

Reiterated

12/12/25

Glaukos price target raised to $125 from $113 at CitiGlaukos price target raised to $125 from $113 at Citi

Michael Sarcone

Jefferies

$130

Buy

8.90%

Upside

Reiterated

11/13/25

Jefferies Keeps Their Buy Rating on Glaukos (GKOS)

Allen Gong

J.P. Morgan

$110→$120

Buy

0.52%

Upside

Reiterated

10/30/25

Glaukos price target raised to $120 from $110 at JPMorganGlaukos price target raised to $120 from $110 at JPMorgan

Patrick Wood

Morgan Stanley

$72

Sell

-39.69%

Downside

Reiterated

10/29/25

Cautious Outlook for Glaukos Amid Regulatory Uncertainty and Valuation Concerns

Anthony Petrone

Mizuho Securities

$150→$130

Buy

8.90%

Upside

Reiterated

07/31/25

Glaukos price target lowered to $130 from $150 at MizuhoGlaukos price target lowered to $130 from $150 at Mizuho

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brandon Vazquez

William Blair

Buy

―

Initiated

01/30/26

Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (NASDAQ: SENS), Perspective Therapeutics (NYSE MKT: CATX) and Glaukos (NYSE: GKOS)

Richard Newitter

Truist Financial

Buy

―

Reiterated

01/29/26

Analysts Are Bullish on These Healthcare Stocks: Capricor Therapeutics (CAPR), Tvardi Therapeutics (TVRD)

Danielle Antalffy

UBS

$145→$150

Buy

25.65%

Upside

Reiterated

01/29/26

UBS Keeps Their Buy Rating on Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

$122

Buy

2.19%

Upside

Reiterated

01/28/26

Wells sees potential upside after Glaukos' iDose repeat dosing label approvedWells sees potential upside after Glaukos' iDose repeat dosing label approved

Ryan Zimmerman

BTIG

$123→$131

Buy

9.73%

Upside

Reiterated

01/28/26

Glaukos (GKOS) Receives a Buy from BTIG

Thomas Stephan

Stifel Nicolaus

$160

Buy

34.03%

Upside

Reiterated

01/26/26

Stifel Nicolaus Remains a Buy on Glaukos (GKOS)

Adam Maeder

Piper Sandler

$165

Buy

38.21%

Upside

Reiterated

01/20/26

Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Glaukos (GKOS)

David Saxon

Needham

$125

Buy

4.71%

Upside

Reiterated

01/14/26

Glaukos: Solid Fundamentals, Strong Multi-Segment Growth, and iDose Trajectory Support a Buy Rating Despite Near-Term Volatility

David Roman

Goldman Sachs

$112→$138

Buy

15.60%

Upside

Reiterated

01/09/26

Glaukos price target raised to $138 from $112 at Goldman SachsGlaukos price target raised to $138 from $112 at Goldman Sachs

Mason Carrico

Stephens

$115→$145

Buy

21.46%

Upside

Reiterated

01/02/26

Glaukos price target raised to $145 from $115 at StephensGlaukos price target raised to $145 from $115 at Stephens

Joanne Wuensch

Citi

$113→$125

Buy

4.71%

Upside

Reiterated

12/12/25

Glaukos price target raised to $125 from $113 at CitiGlaukos price target raised to $125 from $113 at Citi

Michael Sarcone

Jefferies

$130

Buy

8.90%

Upside

Reiterated

11/13/25

Jefferies Keeps Their Buy Rating on Glaukos (GKOS)

Allen Gong

J.P. Morgan

$110→$120

Buy

0.52%

Upside

Reiterated

10/30/25

Glaukos price target raised to $120 from $110 at JPMorganGlaukos price target raised to $120 from $110 at JPMorgan

Patrick Wood

Morgan Stanley

$72

Sell

-39.69%

Downside

Reiterated

10/29/25

Cautious Outlook for Glaukos Amid Regulatory Uncertainty and Valuation Concerns

Anthony Petrone

Mizuho Securities

$150→$130

Buy

8.90%

Upside

Reiterated

07/31/25

Glaukos price target lowered to $130 from $150 at MizuhoGlaukos price target lowered to $130 from $150 at Mizuho

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Glaukos

3 Months

xxx

Success Rate

10/12 ratings generated profit

Average Return

+5.88%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +5.88% per trade.

1 Year

Joanne WuenschCiti

Success Rate

10/13 ratings generated profit

Average Return

+16.42%

reiterated a buy rating 2 months ago

Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +16.42% per trade.

2 Years

xxx

Success Rate

15/19 ratings generated profit

Average Return

+50.62%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.95% of your transactions generating a profit, with an average return of +50.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GKOS Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GKOS has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GKOS average Analyst price target in the past 3 months is 139.10.

Each month's total comprises the sum of three months' worth of ratings.

GKOS Financial Forecast

GKOS Earnings Forecast

Next quarter’s earnings estimate for GKOS is -$0.20 with a range of -$0.30 to -$0.08. The previous quarter’s EPS was -$0.16. GKOS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.

GKOS Sales Forecast

Next quarter’s sales forecast for GKOS is $136.41M with a range of $128.11M to $143.20M. The previous quarter’s sales results were $133.54M. GKOS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.06% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.

GKOS Stock Forecast FAQ

What is GKOS’s average 12-month price target, according to analysts?

Based on analyst ratings, Glaukos’s 12-month average price target is 139.10.

What is GKOS’s upside potential, based on the analysts’ average price target?

Glaukos has 16.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GKOS a Buy, Sell or Hold?

Glaukos has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Glaukos’s price target?

The average price target for Glaukos is 139.10. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $165.00 ,the lowest forecast is $122.00. The average price target represents 16.52% Increase from the current price of $119.38.

What do analysts say about Glaukos?

Glaukos’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of GKOS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Glaukos (GKOS) Stock Forecast & Price Target

GKOS Analyst Ratings

GKOS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Glaukos

GKOS Analyst Recommendation Trends

GKOS Financial Forecast

GKOS Earnings Forecast

GKOS Sales Forecast

GKOS Stock Forecast FAQ

Detailed List of Analyst Forecasts